Abbott Laboratories (NYSE: ABT) has seen a rise in its stock price by 0.02 in relation to its previous close of 134.92. However, the company has experienced a 3.32% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-02-21 that ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.
Is It Worth Investing in Abbott Laboratories (NYSE: ABT) Right Now?
Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio of 17.61x that is above its average ratio. Additionally, the 36-month beta value for ABT is 0.70. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 8 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABT is 1.72B and currently, short sellers hold a 1.06% ratio of that float. The average trading volume of ABT on February 25, 2025 was 5.78M shares.
ABT’s Market Performance
ABT stock saw an increase of 3.32% in the past week, with a monthly gain of 9.52% and a quarterly increase of 15.21%. The volatility ratio for the week is 1.84%, and the volatility levels for the last 30 days are 1.94% for Abbott Laboratories (ABT). The simple moving average for the past 20 days is 3.44% for ABT’s stock, with a 19.36% simple moving average for the past 200 days.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at 11.64% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.34% of loss for the given period.
Volatility was left at 1.94%, however, over the last 30 days, the volatility rate increased by 1.84%, as shares surge +7.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.45% upper at present.
During the last 5 trading sessions, ABT rose by +3.32%, which changed the moving average for the period of 200-days by +27.75% in comparison to the 20-day moving average, which settled at $130.47. In addition, Abbott Laboratories saw 19.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Ford Robert B, who sale 285,388 shares at the price of $131.17 back on Feb 05 ’25. After this action, Ford Robert B now owns 220,059 shares of Abbott Laboratories, valued at $37,435,200 using the latest closing price.
Robert B. Ford, the Officer of Abbott Laboratories, proposed sale 285,388 shares at $131.17 during a trade that took place back on Feb 05 ’25, which means that Robert B. Ford is holding shares at $37,435,238 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.55 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 30.96, with 17.27 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.58. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 13.9.
Currently, EBITDA for the company is 6.83 billion with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 5.86. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
In conclusion, Abbott Laboratories (ABT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
